Excerpt of story provided by Crain's Cleveland Business
Written by Chuck Soder
AcelleRX Therapeutics Inc., a Cleveland Clinic spinoff company, has received a $6.9 million investment that will finance the first clinical trial of its cardiovascular stem cell therapy...
...The company’s lead product, Stromal Derived Factor-1, is given to patients following heart attack or heart failure. It works to repair damaged tissue by promoting cell survival, recruiting stem cells and improving blood flow to damaged tissue...
Read the complete article.
*To view articles two weeks old or less, you must have a print or digital subscription. Articles older than two weeks are free.*
JumpStart cannot be responsible for broken links on third party sites.